



1651
Zhu

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants :	Balasubramanian et al.)	Examiner:
)	To be Assigned
Serial No. :	CIP of 09/997,936 and 10/000,226)	
Cnfrm. No. :	To be Assigned)	Art Unit:
)	To be Assigned
Filed :	Herewith)	
For :	METHOD OF COMPLEXING A PROTEIN BY)	
	THE USE OF A DISPERSED SYSTEM AND)	
	PROTEINS THEREOF)	

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.97-1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

The PTO did receive the following
listed items (s):

Dear Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, applicants hereby bring to the attention of the United States Patent and Trademark Office ("USPTO"), pursuant to 37 C.F.R. §§ 1.97-1.98, the documents listed on the attached PTO-1449 form.

Pursuant to 37 C.F.R. § 1.98(d), references identified with reference numbers 1-8 of U.S. Patent Documents, 9 of Foreign Patent Documents, and 1-48 of Other Documents on the attached PTO-1449 form are not provided, because these references either were previously cited by or submitted to the USPTO in parent U.S. Patent Application Serial No. 09/997,936 or U.S. Patent Application Serial No. 10/000,226, both of which were filed November 30, 2001, of which this application is a continuation-in-part. Reference 49 is attached hereto.

It is respectfully requested that an Examiner-initialed copy of this form be returned to the undersigned.

Respectfully submitted,

Date: July 15, 2004

Tate L. Tschner
Tate L. Tschner
Registration No. 56,048

NIXON PEABODY LLP
Clinton Square, P.O. Box 31051
Rochester, New York 14603-1051
Telephone: (585) 263-1363
Facsimile: (585) 263-1600

Certificate of Mailing - 37 CFR 1.8(a)	
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450, on the date below.	
Date <u>7/15/04</u>	<u>Laura L. Sonnevile</u> Laura L. Sonnevile

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO.	SERIAL NO.
	19226/2083 (R-5661)	CIP of 09/997,936 and 10/000,226
	APPLICANT	
	Balasubramanian et al.	
	FILING DATE	GROUP ART UNIT
	June 21, 2004	To be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE
	1	5,013,556	05/07/1991	Woodle et al.			
	2	5,952,198	09/14/1999	Chan			
	3	4,965,344	Oct. 23, 1990	Hermann			
	4	5,474,892	Dec. 12, 1995	Jakob et al.			
	5	5,679,582	Oct. 21, 1997	Bowie et al.			
	6	5,935,810	Aug. 10, 1999	Friedman et al.			
	7	5,981,714	Nov. 9, 1999	Cheng et al.			
	8	6,348,215 B1	Feb. 19, 2002	Straubinger et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE
	9	WO 99/55306	11/04/1999	WIPO			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

		1	Balasubramanian et al., "Liposomes as Formulation Excipients for Protein Pharmaceuticals: A Model Protein Study," <u>Pharm. Res.</u> , 17(3):344-350 (2000)
		2	Tavio et al., "Human Chorionic Gonadotropin in the Treatment of HIV-Related Kaposi's Sarcoma," <u>Eur. J. Cancer</u> , 34(10):1634-1637 (1998)
		3	Lunardi-Iskandar et al., "Effects of a Urinary Factor From Women in Early Pregnancy on HIV-1, SIV and Associated Disease," <u>Nature Med.</u> , 4(4):428-434 (1998)
		4	Lee-Huang et al., "Lysozyme and RNases as Anti-HIV Components in β -core Preparations of Human Chorionic Gonadotropin," <u>Proc. Natl. Acad. Sci. USA</u> , 96:2678-2681 (1999)
		5	Timasheff et al., "Preferential Binding of Solvent Components to Proteins in Mixed Water-Organic Solvent Systems," <u>Biochem.</u> , 7(7):2501-2513 (1968)
		6	Rariy et al., "Protein Refolding in Predominantly Organic Media Markedly Enhanced by Common Salts," <u>Biotechnol. Bioeng.</u> , 62(6):704-710 (1999)
		7	Rariy et al., "Correct Protein Folding in Glycerol," <u>Proc. Natl. Acad. Sci. USA</u> , 94:13520-13523 (1997)
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO. 19226/2083 (R-5661)	SERIAL NO. CIP of 09/997,936 and 10/000,226
	APPLICANT Balasubramanian et al.	
	FILING DATE June 21, 2004	GROUP ART UNIT To be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

8	Balasubramanian et al., "Interferon- γ -Inhibitory Oligodeoxynucleotides Alter the Conformation of Interferon- γ ," <u>Molecular Pharmacol.</u> , 53:926-932 (1998)
9	Aloj et al., "Interaction of 1, 8-ANS With Human Luteinizing Hormones: A Probe for Subunit Interactions of hCG and hLH," <u>Arch. Biochem. Biophys.</u> , 165:478-479 (1973)
10	Morozova et al., "Stability of Equine Lysozyme. I. Thermal Unfolding Behaviour," <u>Biophys. Chem.</u> , 41:185-191 (1991)
11	Ikeguchi et al., "Evidence for Identity Between the Equilibrium Unfolding Intermediate and a Transient Folding Intermediate: A Comparative Study of the Folding Reactions of α -Lactalbumin and Lysozyme," <u>Biochem.</u> , 25:6965-6972 (1986)
12	Luo et al., "The 28-111 Disulfide Bond Constrains the α -Lactalbumin Molten Globule and Weakens Its Cooperativity of Folding," <u>Proc. Natl. Acad. Sci. USA</u> , 96:11283-11287 (1999)
13	Witzke et al., "Beta-Human Choriogonadotropin Therapy and HIV-Related Kaposi's Sarcoma," <u>Eur. J. Med. Res.</u> , 2:155-158 (1997)
14	Knubovets et al., "Structure, Thermostability, and Conformational Flexibility of Hen Egg-White Lysozyme Dissolved in Glycerol," <u>Proc. Natl. Acad. Sci. USA</u> , 96:1262-1267 (1999)
15	Purohit et al., "Mutants of Human Choriogonadotropin Lacking N-Glycosyl Chains in the α -Subunit. 1. Mechanism for the Differential Action of the N-Linked Carbohydrates," <u>Biochem.</u> , 36:12355-12363 (1997)
EXAMINER DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO. 19226/2083 (R-5661)	SERIAL NO. CIP of 09/997,936 and 10/000,226
	APPLICANT Balasubramanian et al.	
	FILING DATE June 21, 2004	GROUP ART UNIT To be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

		16	Larner, "The Molecular Pathology of Haemophilia," <u>Quarterly J. Med.</u> , 63(242):473-491 (1987)
		17	Toole et al., "Molecular Cloning of a cDNA Encoding Human Antihaemophilic Factor," <u>Nature</u> , 312:342-347 (1984)
		18	Wood et al., "Expression of Active Human Factor VIII From Recombinant DNA Clones," <u>Nature</u> , 312:330-336 (1984)
		19	Fay, "Factor VIII Structure and Function," <u>Thrombosis and Haemostasis</u> , 70(1):63-67 (1993)
		20	Foster et al., "Factor VIII Structure and Function," <u>Blood Reviews</u> , 3:180-191 (1989)
		21	Yoshimoto et al., "Oxidative Refolding of Denatured/Reduced Lysozyme Utilizing the Chaperone-Like Function of Liposomes and Immobilized Liposome Chromatography," <u>Biotechnol. Prog.</u> , 15:480-487 (1999)
		22	Kanaoka et al., "Stabilization of Aerosolized IFN- γ by Liposomes," <u>Int. J. Pharmaceutics</u> , 188:165-172 (1999)
		23	Woodle, "Surface-Modified Liposomes: Assessment and Characterization for Increased Stability and Prolonged Blood Circulation," <u>Chem. Phys. Lipids</u> , 64:249-262 (1993)
		24	Lakowicz, Principles of Fluorescence Spectroscopy, Second Edition, New York, New York:Plenum Publishers, pp. 51-54 (1999)
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT JUL 20 2004 (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO.	SERIAL NO.
	19226/2083 (R-5661)	CIP of 09/997,936 and 10/000,226
	APPLICANT	
	Balasubramanian et al.	
	FILING DATE	GROUP ART UNIT
	June 21, 2004	To be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

25	Gilbert et al., "Specific Membrane Binding of Factor VIII is Mediated by O-Phospho-L-Serine, A Moiety of Phosphatidylserine," <u>Biochem.</u> , 32:9577-9587 (1993)
26	Gilbert et al., "Binding of Human Factor VIII to Phospholipid Vesicles," <u>J. Biol. Chem.</u> , 265(2):815-822 (1990)
27	Hilbich et al., "Aggregation and Secondary Structure of Synthetic Amyloid β A4 Peptides of Alzheimer's Disease," <u>J. Mol. Biol.</u> , 218:149-163 (1991)
28	Hammarström et al., "Structural Mapping of an Aggregation Nucleation Site in a Molten Globule Intermediate," <u>J. Biol. Chem.</u> , 274(46):32897-32903 (1999)
29	Tsai et al., "Formulation Design of Acidic Fibroblast Growth Factor," <u>Pharmaceutical Res.</u> , 10(5):649-659 (1993)
30	Carpenter et al., "Rational Design of Stable Lyophilized Protein Formulations: Some Practical Advice," <u>Pharmaceutical Res.</u> , 14(8):969-975 (1997)
31	Foster et al., "Synthetic Factor VIII Peptides With Amino Acid Sequences Contained Within the C2 Domain of Factor VIII Inhibit Factor VIII Binding to Phosphatidylserine," <u>Blood</u> , 75(10):1999-2004 (1990)
32	Kalafatis et al., "Factor Va-Membrane Interaction is Mediated by Two Regions Located on the Light Chain of the Cofactor," <u>Biochem.</u> , 33:486-493 (1994)
33	Lecompte, et al. "Electrostatic and Hydrophobic Interactions Are Involved in Factor Va Binding to Membranes Containing Acidic Phospholipids," <u>J. Biol. Chem.</u> , 269(3):1905-1910 (1994)
34	Saenko et al., "A Mechanism for Inhibition of Factor VIII Binding to Phospholipid by von Willebrand Factor," <u>J. Biol. Chem.</u> , 270(23):13826-13833 (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE SECOND SUPPLEMENTARY INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO. 19226/2083 (R-5661)	SERIAL NO. CIP of 09/997,936 and 10/000,226
	APPLICANT Balasubramanian et al.	
	FILING DATE June 21, 2004	GROUP ART UNIT To be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

35	Scandella et al., "In Hemophilia A and Autoantibody Inhibitor Patients: The Factor VIII A2 Domain and Light Chain Are Most Immunogenic," <u>Thrombosis Res.</u> , 101:377-385 (2001)
36	Woodle et al., "Versatility in Lipid Compositions Showing Prolonged Circulation with Sterically Stabilized Liposomes," <u>Biochimica et Biophysica Acta</u> , 1105:193-200 (1992)
37	Klibanov et al., "Amphipathic Polyethyleneglycols Effectively Prolong the Circulation Time of Liposomes," <u>FEBS Letters</u> , 268:235-237 (1990)
38	Papahadjopoulos et al., "Sterically Stabilized Liposomes: Improvements in Pharmacokinetics and Antitumor Therapeutic Efficacy," <u>Proc. Natl. Acad. Sci. USA</u> , 88:11460-11464 (1991)
39	Lasic et al., "Sterically Stabilized Liposomes: A Hypothesis on the Molecular Origin of the Extended Circulation Times," <u>Biochimica et Biophysica Acta</u> , 1070:187-192 (1991)
40	Pan et al., "Proposed Structure of the A Domains of Factor VIII by Homology Modelling," <u>Nature Structural Biol.</u> , 2(9):740-744 (1995)
41	Ptitsyn et al., "Evidence For a Molten Globule State as a General Intermediate In Protein Folding," <u>FEBS Letters</u> , 262(1): 20-24 (1990)
42	Kirby et al., "Preparation of Liposomes Containing Factor VIII for Oral Treatment of Haemophilia," <u>J. Microencapsul.</u> , 1:33-45 (1984)
43	Kirby et al., "Incorporation of Factor VIII Into Liposomes," <u>Liposome Technology</u> , Vol. II, Boca Raton, FL: CRC Press, Inc. pp. 69-81 (1984)
44	Hemker et al., "Oral Treatment of Haemophilia A by Gastrointestinal Absorption of Factor VIII Entrapped in Liposomes," <u>The Lancet</u> , 1:70-71 (1980)
45	Gilbert et al., "Specificity of Phosphatidylserine-Containing Membrane Binding Sites for Factor VIII," <u>J. Biol. Chem.</u> , 267(22):15861-15868 (1992)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use several sheets if necessary) (PTO-1449)	ATTY. DOCKET NO. 19226/2083 (R-5661)	SERIAL NO. CIP of 09/997,936 and 10/000,226
	APPLICANT Balasubramanian et al.	
	FILING DATE June 21, 2004	GROUP ART UNIT To be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANS- LATION IF APPRO- PRIATE

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

		46	Röstin et al., "B-Domain Deleted Recombinant Coagulation Factor VIII Modified with Monomethoxy Polyethylene Glycol," <u>Bioconjugate Chem.</u> , 11:387-396 (2000)
		47	"Stability of Protein Pharmaceuticals: Part A: Chemical and Physical Pathways of Protein Degradation," in Ahern, eds., <u>Pharmaceutical Biotechnology</u> , Vol. 2, New York, New York:Plenum Press, pp. vii-xvii (1992)
		48	"Stability of Protein Pharmaceuticals: Part B: In Vivo Pathways of Degradation and Strategies for Protein Stabilization," in Ahern, eds., <u>Pharmaceutical Biotechnology</u> , Vol. 3, New York, New York:Plenum Press, pp. vii-viii (1992)
		49	Balasubramanian et al., "Physical Instability and Liposomal Formulation of a Model Protein," <u>AAPS PharmSci.</u> , Abstract No. 3622 (1998).
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			